Anti-sCTLA-4 antibody 4018
High affinity polyclonal antibody specifically targeting the soluble isoform of CTLA-4 (sCTLA-4)
Catalogue number crb2005178 Antibody Anti-sCTLA-4 antibody 4018 Antigen Peptide KLH conjugated synthetic peptide crb1200374e Protein ID UniProtKB - P16410 Aliases Cytotoxic T-lymphocyte protein 4, CD152 (cluster of differentiation 152) Cross-Reactivity Human Target Protein Species Human Host Species Rabbit Antibody Type Polyclonal Concentration 0.93mg/ml Validation WB/ELISA Target sCTLA-4 Storage Stabilisers This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -80°C for long term storage. Avoid repeated freeze/ thaw cycles. Disease Area Immune homeostasis Specificity Soluble CTLA-4 Storage This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -80°C for long term storage. Avoid repeated freeze/ thaw cycles. Citations
Esposito, L., Hunter, K., Clark, J., Rainbow, D., Stevens, H., Denesha, J., Duley, S., Dawson, S., Coleman, G., Nutland, S., Bell, G., Moran, C., Pekalski, M., Todd, J. and Wicker, L. (2014). Investigation of Soluble and Transmembrane CTLA-4 Isoforms in Serum and Microvesicles. J Immunol, 193(2), 889-900. PMID: 24928993
Sekiya, T. and Takaki, S. (2019). RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4. Sci Rep, 9(1). PMID: 31061392
Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) in an immunoglobulin superfamily receptor important for downregulating immune responses. CTLA4 is expressed in T-cells where it transmits an inhibitory signal to the cells.
The secreted soluble form of CTLA-4 (sCTLA-4) lacks the transmembrane domain as well as the membrane proximal cysteine residue required for covalent homodimerization and therefore sCTLA-4 is only present in monomeric form.
In human and mouse sCTLA-4 mRNA expression is mainly detected in resting T-cells, at levels similar to transmembrane CTLA-4 (Tm-CTLA-4) mRNA, however following T-cell activation, Tm-CTLA-4 is upregulated and becomes the predominant transcript. Mutations in CTLA4 are associated with multiple autoimmune diseases, including type 1 diabetes (T1D), Graves’ disease (GD), rheumatoid arthritis and celiac disease, an increase of sCTLA-4 is also seen in autoimmune diseases.